The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globe Life Inc. ("Globe Life" or "the Company") (NYSE:GL) for ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options New York, ...

Q1 GAAP EPS of -$0.90 beats by $0.05. Akero's cash, cash equivalents and short-term marketable securities as of March 31, ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of ...

May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by ...

Stockholders' Equity: Grew to $846.25 million, up from $535.31 million at the end of the previous year.

BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS ...

Browse analyst ratings and price targets on all stocks.

Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options ...